Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
AUROBINDO PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
AUROBINDO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 715 | 320 | - | |
Low | Rs | 397 | 231 | - | |
Sales per share (Unadj.) | Rs | 424.2 | 95.1 | - | |
Earnings per share (Unadj.) | Rs | 32.9 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 54.1 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 458.1 | 74.6 | - | |
Shares outstanding (eoy) | m | 585.94 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 2.9 | 45.3% | |
Avg P/E ratio | x | 16.9 | -11.5 | -147.2% | |
P/CF ratio (eoy) | x | 10.3 | -13.9 | -74.1% | |
Price / Book Value ratio | x | 1.2 | 3.7 | 32.9% | |
Dividend payout | % | 9.1 | 0 | - | |
Avg Mkt Cap | Rs m | 325,753 | 46,446 | 701.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 35,223 | 2,915 | 1,208.3% | |
Avg. sales/employee | Rs Th | 0 | 3,739.2 | - | |
Avg. wages/employee | Rs Th | 0 | 679.0 | - | |
Avg. net profit/employee | Rs Th | 0 | -942.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 248,554 | 16,052 | 1,548.4% | |
Other income | Rs m | 2,906 | 112 | 2,585.1% | |
Total revenues | Rs m | 251,460 | 16,165 | 1,555.6% | |
Gross profit | Rs m | 37,070 | -2,782 | -1,332.6% | |
Depreciation | Rs m | 12,446 | 693 | 1,796.4% | |
Interest | Rs m | 1,405 | 435 | 323.1% | |
Profit before tax | Rs m | 26,125 | -3,797 | -688.0% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,849 | 237 | 2,886.5% | |
Profit after tax | Rs m | 19,277 | -4,045 | -476.6% | |
Gross profit margin | % | 14.9 | -17.3 | -86.1% | |
Effective tax rate | % | 26.2 | -6.2 | -419.5% | |
Net profit margin | % | 7.8 | -25.2 | -30.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 214,599 | 11,757 | 1,825.3% | |
Current liabilities | Rs m | 114,938 | 6,615 | 1,737.5% | |
Net working cap to sales | % | 40.1 | 32.0 | 125.2% | |
Current ratio | x | 1.9 | 1.8 | 105.1% | |
Inventory Days | Days | 21 | 111 | 18.6% | |
Debtors Days | Days | 66 | 124 | 52.9% | |
Net fixed assets | Rs m | 176,668 | 6,853 | 2,577.9% | |
Share capital | Rs m | 586 | 75 | 786.1% | |
Net worth | Rs m | 268,399 | 12,599 | 2,130.3% | |
Long term debt | Rs m | 6,190 | 4,428 | 139.8% | |
Total assets | Rs m | 392,125 | 23,801 | 1,647.5% | |
Interest coverage | x | 19.6 | -7.7 | -253.4% | |
Debt to equity ratio | x | 0 | 0.4 | 6.6% | |
Sales to assets ratio | x | 0.6 | 0.7 | 94.0% | |
Return on assets | % | 5.3 | -15.2 | -34.8% | |
Return on equity | % | 7.2 | -32.1 | -22.4% | |
Return on capital | % | 10.0 | -19.8 | -50.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,868 | 1,370 | 1,741.9% | |
From Investments | Rs m | -39,778 | -421 | 9,454.8% | |
From Financial Activity | Rs m | 18,144 | 4,018 | 451.5% | |
Net Cashflow | Rs m | 2,298 | 4,968 | 46.2% |
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: IOL CHEMICALS & PHARM. WANBURY LINK PHARMA SMS LIFESCIENCES INDIA ZIM LABORATORIES
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.